A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

To join this study, you must be at least 18 years old. You need to have been diagnosed with triple-negative breast cancer that was stages I, II, or III. A key requirement is that after your initial chemotherapy and surgery, there were still some cancer cells found in your breast or nearby lymph nodes.

You should have completed at least six cycles of certain chemotherapy types before your surgery, and not have received any other cancer medication after your surgery but before joining the study. Your heart function should be good, and you should be generally well enough to participate, as assessed by your doctor. Importantly, you shouldn't have cancer spread to other parts of your body (stage IV).

There are also some medical conditions or previous treatments that would prevent you from taking part, such as a history of other invasive breast cancer, or severe medical issues that could make participating unsafe.

If you join this study, you will be assigned to one of three treatment groups. You will receive either Dato-DXd on its own, Dato-DXd with Durvalumab, or one of the standard treatments chosen by your doctor (Capecitabine or Pembrolizumab). The treatments are given through infusions (drips) or as pills, and you will have regular clinic visits, blood tests, and scans to monitor your health and the effects of the treatment.

This is an 'open-label' study, which means both you and your doctor will know which treatment you are receiving. The study involves ongoing treatment and visits, followed by regular check-ups to see how you are doing in the long term. The total duration of your active treatment will depend on the specific drugs you receive and how your body responds, but you will be followed for a significant period to track your health.